Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy

Clinical Rheumatology

Volumn 32, Issue 5, 2013, Pages 585-590

  Dirven, L ^a   Klarenbeek, N B ^a   Van Den Broek, M ^a   Van Groenendael, J H L M ^b   De Sonnaville, P B J ^c   Kerstens, P J S M ^d   Huizinga, T W J ^a   Dijkmans, B A C ^d,e   Lems, W F ^d,e   Allaart, C F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Franciscus Hospital   (Netherlands)

^c Admiraal de Ruyter Hospital   (Netherlands)

^d Reade   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alanine transferase (ALT); Methotrexate; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SMOKING;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; ODDS RATIO; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878693069     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2136-8     Document Type: Article

References (19)

1. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68(7):1086-1093
2. Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcon GS et al (1993) Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36(3):329-335
3. Visser K, van der Heijde DM (2009) Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 27(6):1017-1025
4. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52(11):3381-3390
5. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ et al (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(6):914-921
6. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 69(1):43-47
7. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM et al (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69(9):1612-1617
8. Kremer JM, Lee RG, Tolman KG (1989) Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 32(2):121-127
9. Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y et al (1999) Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 28(5):273-281
10. Whiting-O'Keefe QE, Fye KH, Sack KD (1991) Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90(6):711-716
11. Langman G, Hall PM, Todd G (2001) Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 16(12):1395-1401
12. Bourre-Tessier J, Haraoui B (2010) Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 37(7):1416-1421
13. Visser K, van Aken J, van Dongen H, Lard LR, Ronday HK, Speyer I et al (2009) Disease activity, joint damage and functional disability and the effect of methotrexate treatment in patients with undifferentiated arthritis with or without anti-citrullinated protein antibodies (abstract). Arthritis Rheum 60(10):1620
14. Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES et al (2003) Impact of smoking on histological liver lesions in chronic hepatitis C. Gut Jan 52(1):126-129
15. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S et al (2001) Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 34(1):121-125
16. Simon CH, Dijkmans BA, Breedveld FC (1997) Variations in the monitoring and management of the side effects of antirheumatic drugs by means of laboratory tests. Clin Exp Rheumatol 15(6):633-639
17. Simon CH, Vliet Vlieland TP, Dijkmans BA, Bernelot Moens HJ, Janssen M, Hazes JM et al (1998) Laboratory screening for side effects of disease modifying antirheumatic drugs in daily rheumatological practice. Scand J Rheumatol 27(3):170-179
18. Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM (1990) Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clin Rheumatol 9(3):333-341
19. Lester SE, Proudman SM, Lee AT, Hall CA, McWilliams L, James MJ et al (2009) Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. Intern Med J 39(5):296-303